Why Ilika (AIM: IKA) just raised £4.56m as its batteries reach paying customers

Ilika, the AIM-listed solid-state battery developer behind the Stereax and Goliath battery platforms, has raised £4.56 million through an oversubscribed share placing, with a further retail offer to existing shareholders closing this week. The fundraise lands at a genuine inflection point for the company, which has spent over two decades in development and is now beginning to book its first commercial revenue from both battery lines. Retail investors weighing up a company that still posts steep losses, but appears to be crossing a real technical and commercial threshold, are asking whether this raise marks the start of Ilika’s payoff period or simply funds another year of expensive development.

What does Ilika actually make, and why are Stereax and Goliath two different businesses?

Ilika, founded in 2004 and based in Romsey in the UK, develops solid-state batteries, a technology that replaces the flammable liquid electrolyte used in conventional lithium-ion cells with a solid material, promising greater safety, higher energy density and a longer working life. The company runs two distinct product lines aimed at very different markets. Stereax is a small-format battery designed for medical and industrial applications including neurostimulation devices, cardiac sensing implants, smart orthopaedic and orthodontic devices, smart contact lenses and industrial sensors. Goliath is a large-format battery aimed at electric vehicles and cordless consumer electronics, where higher capacity and power density matter more than miniaturisation.

Running two separate product lines gives Ilika two distinct routes to commercial revenue and two different sets of industry partners, but it also means the company is effectively pursuing two capital-intensive commercialisation efforts in parallel rather than concentrating all of its resources on a single product. For a company of Ilika’s size, with around 70 employees, that dual-track strategy places real demands on management focus and cash.

For a retail investor, the practical takeaway is that Stereax, aimed at medical devices, is generally viewed as closer to steady commercial revenue given the smaller scale and cost of the batteries involved, while Goliath, aimed at automotive customers, represents a larger potential market but a longer and more capital-intensive path to meaningful revenue given the scale of manufacturing required to serve vehicle production volumes.

Why did Ilika raise nearly £5 million just as its batteries are reaching commercial customers?

Ilika raised £4.56 million before expenses through an oversubscribed placing of 16.3 million new shares at 28 pence each, alongside a separate retail offer targeting up to a further £500,000 from existing UK shareholders, priced at the same 28 pence and due to close on 7 July 2026. Chief executive Graeme Purdy and chairman Keith Jackson both participated in the raise through director subscriptions, adding new shares to their existing holdings at the same price offered to outside investors.

The company intends to combine the new proceeds with its existing cash balance of £5.3 million to fund specific, named commercial milestones across both battery lines, rather than general working capital. This kind of targeted use-of-proceeds language, tied to identifiable near-term milestones rather than broad operational runway, is generally a more reassuring structure for retail investors than a raise described only in general terms.

The risk, as with any small-cap fundraise, is dilution. The placing represented approximately 8.85% of Ilika’s existing share capital, and full take-up of the combined raise would take total shares in issue to just under 199 million. Retail investors should weigh the specific commercial milestones this capital is meant to unlock against the incremental dilution to existing holdings.

What does the first Goliath revenue and 27-company evaluation pipeline actually tell investors?

For the financial year ended 30 April 2026, Ilika reported total revenue of around £1.1 million, similar to the prior year, but the composition of that revenue changed in a way management has flagged as significant. The figure included £100,000 of recurring Stereax electrode sales, unchanged from the prior year, but also included Ilika’s first ever Goliath revenue, a £74,000 deal with a top-tier automotive parts supplier. Independent analyst commentary has described this modest sum as an important signal rather than a meaningful revenue contributor in its own right, since it marks the first time an automotive customer has paid Ilika directly for Goliath-related work.

Alongside this first Goliath revenue, Ilika has said it maintains a pipeline of evaluation agreements with 27 separate companies spanning automotive, defence and consumer sectors, and that an automotive customer has independently validated its 2Ah P1 prototype batteries as performing to specification and sitting within the leading group of solid-state batteries globally.

The retail investor read here is one of degree rather than a single defining event. A 27-company evaluation pipeline and a first small automotive revenue contract are meaningful evidence that Ilika’s technology is being taken seriously by real industrial customers, but evaluation agreements do not guarantee conversion into large, recurring commercial contracts, and the actual revenue booked to date remains very small relative to the company’s ongoing cash burn.

How close is Ilika’s Stereax battery to generating its first royalty payments?

A meaningful portion of the new fundraise, up to £2 million, is earmarked specifically for advancing Stereax’s commercial rollout with Cirtec Medical, a medical device manufacturing partner, covering product optimisation and testing and validation of Ilika’s M300 battery. Critically, the company has said this work is intended to trigger the commencement of its first royalty payments, which would be generated once M300 batteries are delivered into customer testing programmes.

Ilika itself has described reaching this royalty stage as a critical commercial milestone that would validate its underlying licensing business model, in which the company earns ongoing royalty income from manufacturing partners producing batteries using its technology, rather than manufacturing and selling batteries directly at scale itself. A licensing model of this kind can, if it works, generate higher-margin recurring revenue without Ilika needing to fund its own large-scale battery manufacturing capacity.

The risk for retail investors is that this remains a milestone still to be achieved rather than one already delivered. The fundraise proceeds are explicitly intended to fund the work required to reach first royalty payments, meaning the milestone itself, and the validation of the licensing model it represents, is a near-term target rather than a confirmed outcome.

Why does shipping 10Ah Goliath prototypes to customers matter more than earlier prototype milestones?

Ilika has begun shipping 10Ah solid-state battery prototypes to automotive and industrial customers, representing a five-fold increase in capacity compared with the 2Ah P1 cells it delivered to customers in mid-2024. These new Goliath cells are produced on an automated pilot production line completed in October 2025 and incorporate a proprietary oxide coating designed to improve safety, a detail the company has highlighted as a specific technical differentiator.

The jump from 2Ah to 10Ah cells matters because battery capacity scaling is one of the central technical and manufacturing challenges facing any solid-state battery developer moving from laboratory demonstration toward commercially useful products. Ilika has also produced early samples of even larger 50Ah cells for internal testing, with customer shipments of those larger cells expected to follow later in 2026 once feedback from current prototypes has been incorporated.

For retail investors, this progression represents genuine, verifiable technical advancement rather than simply promotional language, since it is measured in a specific, checkable unit, battery capacity, and tied to an automated production line that has already been completed. The remaining risk is the gap between shipping prototypes for evaluation and securing binding, volume production orders from automotive customers, which typically involves lengthy qualification processes before large-scale commercial adoption.

What do independent estimates about cost and weight savings mean for Ilika’s EV ambitions?

Independent analysis from automotive consultancy Balance Batteries has estimated that Ilika’s solid-state battery technology could reduce electric vehicle battery pack weight by 20% and cut manufacturing costs by approximately £2,500 per vehicle, figures that, if borne out in real-world automotive applications, would represent a meaningful competitive advantage over conventional lithium-ion battery packs.

These kinds of third-party technical estimates carry more credibility than a company’s own marketing claims about its technology, since they come from an industry-focused consultancy rather than Ilika itself. They also help explain why automotive customers might be willing to engage in lengthy, multi-year evaluation processes with a still-small supplier like Ilika rather than sourcing exclusively from established battery cell manufacturers.

The caveat for retail investors is that estimated weight and cost savings at a theoretical or prototype stage do not automatically translate into adoption at vehicle production scale, which depends on Ilika successfully scaling manufacturing, securing supply chain partnerships, and navigating the automotive industry’s typically conservative and lengthy qualification timelines before any of these projected savings show up in an actual production vehicle.

Why does Ilika’s weak financial profile sit alongside genuinely strong technical momentum?

Ilika’s underlying financial position remains challenging by conventional measures. Full-year revenue actually declined compared with the prior year in the period before the most recent results, its EBITDA loss excluding share-based payments widened to approximately £6.2 million from £5.2 million, and cash and cash equivalents fell to £5.3 million from £8 million over the same period, before the latest fundraise replenished the balance. Independent analyst screening has flagged Ilika as carrying weak financial performance overall, citing revenue decline, ongoing losses and negative operating and free cash flow.

At the same time, that same independent screening has separately noted strong technical share price momentum, and the company’s progression through capacity milestones, customer validation, and now its first Goliath revenue represents tangible operational progress that a purely financial statement view can understate. This is a common pattern for pre-commercial deep technology companies, where genuine scientific and engineering achievement can run well ahead of the revenue and profit figures a traditional financial analysis would emphasise.

Retail investors should hold both pictures in mind simultaneously rather than resolving the tension in either direction. Ilika’s technology appears to be genuinely progressing toward commercial relevance, but the company remains dependent on external capital to fund that progress, and continued fundraising, with the dilution that comes with it, should be expected to continue until revenue scales meaningfully closer to the company’s cost base.

What are AIM forum investors debating about Ilika’s battery technology and its defence potential?

Ilika’s retail investor forums have developed a notably technical character, with detailed debates among shareholders about the engineering feasibility of scaling the company’s battery cells into larger applications. One recurring thread involves whether Ilika’s 10Ah Goliath cell can be effectively stacked into larger battery packs suitable for demanding applications such as defence platforms or maritime drones, with proponents arguing that modular battery engineering, building larger packs from smaller cell building blocks, is a well-established industry approach rather than a stretch of the technology’s original design intent.

This defence and dual-use angle has grown alongside broader UK and European interest in rearmament and defence-sector supply chains, and Ilika’s evaluation pipeline explicitly includes defence sector companies alongside its automotive and consumer customers. Forum participants engaging in this kind of detailed technical debate suggest a retail shareholder base that has developed genuine subject-matter familiarity with the underlying battery engineering, rather than trading purely on headline news.

For a retail investor newer to the stock, this technical forum debate is a useful signal of engaged, informed community interest, but it is not a substitute for the company’s own confirmed customer contracts and revenue disclosures. Enthusiasm about theoretical defence applications should be weighed against the fact that Ilika has not, at the time of writing, disclosed specific defence sector revenue or contracts to match the automotive and medical progress detailed elsewhere in its recent updates.

Key takeaways for retail investors watching Ilika

• Ilika (AIM: IKA) has raised £4.56 million through an oversubscribed placing, with a further retail offer closing 7 July 2026, to fund named commercial milestones across its Stereax and Goliath solid-state battery platforms.
• The company booked its first ever Goliath battery revenue, a £74,000 deal with a top-tier automotive parts supplier, alongside a pipeline of evaluation agreements with 27 companies spanning automotive, defence and consumer sectors.
• Up to £2 million of new funding is earmarked for advancing Stereax toward its first royalty payments through a partnership with Cirtec Medical, a milestone the company describes as critical validation of its licensing business model.
• Ilika has begun shipping 10Ah Goliath battery prototypes, a five-fold capacity increase over its earlier 2Ah cells, produced on an automated pilot line completed in October 2025, with larger 50Ah cell samples now also in testing.
• Independent analysis has estimated Ilika’s technology could cut EV battery pack weight by 20% and reduce manufacturing costs by roughly £2,500 per vehicle, though these remain theoretical estimates pending production-scale adoption.
• The company’s underlying financial profile remains weak, with widening losses and declining cash reserves before the latest raise, even as independent screening has separately noted genuinely strong technical and share price momentum.
• AIM forum discussion has developed a notably technical character, with active debate about the feasibility of scaling Ilika’s battery cells into defence and maritime applications alongside its established automotive and medical device focus.